Redo TAVI in a case of mixed structural and non-structural degeneration of a supra-annular transcatheter heart valve

Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Given the longer life expectancy of these patients, the bioprosthetic valve will eventually fail, and aortic valve reintervention may be necessary. Thus, redo-TAVR will likely increase in the future as younger patients are expected to outlive their transcatheter bioprosthesis. However, while TAVR has already proven to be safe and effective treatment for patients with degenerated surgical bioprostheses, little is known about the optimal approach to redo-TAVR. A multitude of clinical and anatomical factors need to be meticulously evaluated to determine candidacy and the feasibility of redo-TAVR in patients with transcatheter valve failure.

In these videos, we will guide the viewer with a step-by-step approach trough the pre-procedural planning and the intra-procedural aspects of a redo-TAVR procedure for the treatment of a failed self-expanding supra-annular transcatheter aortic bioprosthesis.